Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
A. M. Pappas & Associates
AddedFeb 15, 2024
UpdatedJun 28, 2026
A. M. Pappas & Associates

A. M. Pappas & Associates

Operating

M. Pappas & Associates: A Durham-based venture capital firm managing $350M, investing in life sciences, and fostering entrepreneurial growth.

Location
Durham, NC, US
Founded
1994
Firm
Compare
Portfolio
Employees
Website

A. M. Pappas & Associates is a Durham-based venture capital firm managing $350 million in capital. The firm focuses on life sciences investments in the United States and Canada, typically participating in Series A to Series D rounds. With a portfolio of over 65 companies, A. M. Pappas & Associates demonstrates a commitment to fostering entrepreneurial growth in the biotech and healthcare sectors.

Notable portfolio companies include BrainCells, CeNeRx Biopharma, and Elitra Pharmaceuticals. The firm's investment philosophy emphasizes nurturing promising companies, products, and technologies. Beyond its core investment activities, A. M. Pappas & Associates supports philanthropic interests in life sciences and public education, showcasing a broader commitment to societal advancement.

A. M. Pappas & Associates - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments9
Current Portfolio Count6
Total Portfolio Exits1

Top Investment Stages

Series Unknown3 (33.3%)
Series A2 (22.2%)
Series B2 (22.2%)
Series D1 (11.1%)
Undisclosed1 (11.1%)

Stage Mix

Series Unknown 33%Series A 22%Series B 22%Series D 11%Undisclosed 11%

Concentration shown as share of disclosed investments by stage.

Recent Investments

CeNeRx Biopharma logo

CeNeRx Biopharma

BrainCells logo

BrainCells

Emerald Bioagriculture logo

Emerald Bioagriculture

Dynogen Pharmaceuticals logo

Dynogen Pharmaceuticals

Sensys Medical logo

Sensys Medical

Cognetix logo

Cognetix

Elitra Pharmaceuticals logo

Elitra Pharmaceuticals

Variagenics logo

Variagenics

Copernicus Therapeutics logo

Copernicus Therapeutics

A. M. Pappas & Associates - Similar Investment Firms

Pappas Capital logo

Pappas Capital

pappas-capital.com

MPM Capital logo

MPM Capital

mpmbioimpact.com

Hatteras Venture Partners logo

Hatteras Venture Partners

hatterasvp.com

Plaisance Capital Management logo

Plaisance Capital Management

plaisancecap.com

Pappy Capital logo

Pappy Capital

pappycap.com

Mass Medical Angels logo

Mass Medical Angels

massmedangels.com

Ampersand Capital Partners logo

Ampersand Capital Partners

PharmaBio Investments logo

PharmaBio Investments

Aurora Funds logo

Aurora Funds

aurorafunds.com.au

Piedmont Capital Investments logo

Piedmont Capital Investments

piedmontinvest.com

US Investment Partners logo

US Investment Partners

Ra Capital Management logo

Ra Capital Management

racap.com

Epidarex Capital logo

Epidarex Capital

epidarex.com

Forepont Capital Partners logo

Forepont Capital Partners

forepont.com

BioImpact Capital logo

BioImpact Capital

A. M. Pappas & Associates - Classification

Also Known As
  • A. M. Pappas & Associates, LLC
NAICS
  • 520000Finance and Insurance
SIC
  • 6000Depository Institutions